EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience

Umair Mahmood, Eleni Josephides, Nicholas Coupe, Daniel Smith iD, Shahreen Ahmad, Omar Al-Salihi, Sze M Mak, Meenali Chitnis iD, Alexandros Georgiou iD, Daniel Ajzensztejn, Eleni Karapanagiotou iD, Geoff S Higgins und 3 weitere

Cancers · 25.12.2025 · 18 (1) · 71

DOI: 10.3390/cancers18010071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 25.12.2025. Verfasst von Umair Mahmood und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guy's Cancer Academy and Friends of Guy's and St. Thomas Hospital Charity, Guy’s Cancer Academy and Friends of Guy’s and St. Thomas Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We conducted the largest multinational review to date evaluating outcomes following radiotherapy for non-small cell lung carcinoma (NSCLC) patients with oligoprogressive disease (OPD) on immune checkpoint inhibitors (ICIs).

Methods

Patients with NSCLC irradiated to ≤5 progressive lesions while receiving ICIs between 2010 and 2023 were identified. We evaluated predictors of local control (LC), progression-free survival (PFS), and overall survival (OS). Patient demographics, disease characteristics, and survival were analyzed using the Wilcoxon test, Kaplan-Meier methods, and uni-/multivariate Cox models.

Results

Out of 1178 treated patients, 103 eligible ones were included. The median OPD lesion was 1; the most common site was the lung (n = 33). The median LC of irradiated OPD lesions was not reached. Median PFS and OS were 6.90 (5.75–12.91) and 23.46 (17.54–37.16) months, respectively. Patient demographics, tumor pathological factors, number of OPD lesions, cumulative tumor volume, radiation modality, and OPD response to prior ICIs before radiation were not associated with these three outcomes. However, LC was associated with intermediate/high radiation doses (p = 0.005) and local response to radiation (p = 0.007). Improved PFS was associated with visceral OPD sites following radiation (p = 0.01). A favorable OS was associated with intermediate/high radiation doses (p = 0.01), local response to radiation (p = 0.006), and duration of last ICI before OPD (p = 0.03).

Conclusions

Promising outcomes were observed with ICI and radiation for visceral OPD at intermediate/high doses. Prolonged ICI use before OPD and local response to radiotherapy improved survival. These data can contribute towards guidance of multidisciplinary clinical decision-making for managing OPD in NSCLC patients receiving ICIs.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsnon-small cell lung carcinomaoligometastasesradiotherapysurvival outcomes

Autor:innen und Institutionen

  • Department of Oncology, Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, UK.
  • Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Department of Radiology, Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, UK.
  • Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

ORCID-Profile: Daniel Smith, Meenali Chitnis, Alexandros Georgiou, Eleni Karapanagiotou, Michael Skwarski

Förderung

  • Guy's Cancer Academy and Friends of Guy's and St. Thomas Hospital Charity
  • Guy’s Cancer Academy and Friends of Guy’s and St. Thomas Hospital Charity

Zitieren

APA

Mahmood, U., Josephides, E., Coupe, N., Smith, D., Ahmad, S., Al-Salihi, O., Mak, S. M., Chitnis, M., Georgiou, A., Ajzensztejn, D., Karapanagiotou, E., Higgins, G. S., Panakis, N., Schoenfeld, J. D., & Skwarski, M. (2025). Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience. Cancers, 18(1), 71. https://doi.org/10.3390/cancers18010071

Vancouver

Mahmood U, Josephides E, Coupe N, Smith D, Ahmad S, Al-Salihi O, et al. Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience. Cancers. 2025;18(1):71. doi:10.3390/cancers18010071

BibTeX
@article{Mahmood2025,
  author = {Mahmood, Umair and Josephides, Eleni and Coupe, Nicholas and Smith, Daniel and Ahmad, Shahreen and Al-Salihi, Omar and Mak, Sze M and Chitnis, Meenali and Georgiou, Alexandros and Ajzensztejn, Daniel and Karapanagiotou, Eleni and Higgins, Geoff S and Panakis, Niki and Schoenfeld, Jonathan D and Skwarski, Michael},
  title = {Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience},
  journal = {Cancers},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {71},
  doi = {10.3390/cancers18010071}
}
Kostenlos starten →